Fig. 1

CD362⁺ UC-hMSCs decrease E. coli-induced lung injury. CD362⁺ UC-hMSCs ameliorated the decrement in arterial oxygenation to a similar degree as heterogeneous BM or UC-hMSC therapy (a). Heterogeneous BM and CD362⁺ UC-hMSC reduced the wet to dry ratio of lung tissue (b), while all hMSC types restored the decrement in static lung compliance (c), reduced lung E. coli bacterial load (d), and dampened total infiltrating cell count in BAL (e) compared to vehicle. Heterogeneous BM and UC CD362⁺, but not heterogeneous UC-hMSC significantly reduced BAL neutrophil counts (f). All 3 cell types attenuated the increase in BAL IL-1β (g), CINC-1 (h), and IL-6 (i) concentrations. Abbreviations: vehicle, treatment with vehicle alone; BM, bone marrow-derived heterogeneous hMSC; UC, umbilical cord-derived heterogeneous hMSC; UC 362+, umbilical cord-derived CD362⁺ hMSC; BAL, bronchoalveolar lavage; IL-1β, interleukin 1 beta; CINC-1, cytokine-induced neutrophil chemoattractant 1; IL-6, interleukin 6. Error bars represent standard deviation. *Significantly (P < 0.05) different from the vehicle control group